Condition
Advanced Biliary Tract Carcinoma clinical trials and research
As of November 12, 2026, Find a Trial lists 6 Advanced Biliary Tract Carcinoma clinical trials that are recruiting, at sites in 3 countries (most in United States (4), France (1), China (1)). By phase: Phase 2 (4), Phase 1/2 (1), Phase 4 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 6Clinical trials
- 3Countries
Newest Advanced Biliary Tract Carcinoma clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Morning versus afternoon immunotherapy for advanced or metastatic solid tumors | Phase 4 | Portland, Oregon | Recruiting | Feb 12, 2026 |
| Adebrelimab plus gemcitabine, cisplatin, and simvastatin for advanced biliary tract cancer | Phase 1/2 | Wuhan, Hubei | Recruiting | Feb 6, 2026 |
| MP0317 plus gemcitabine‑cisplatin and durvalumab for first-line advanced biliary tract cancer | Phase 2 | Besançon and 10 other locations | Recruiting | Jun 25, 2025 |
| At-home cancer treatment versus clinic-based treatment for advanced cancer patients | Phase 2 | Jacksonville, Florida and 1 other locations | Recruiting | Aug 1, 2023 |
| CPI-613 combined with hydroxychloroquine and chemotherapy for advanced solid tumors | Phase 2 | Chicago, Illinois | Recruiting | Feb 17, 2023 |
| Using olanzapine to help cancer patients regain appetite and manage weight loss | Phase 2 | Portland, Oregon | Recruiting | Jan 30, 2023 |
All recruiting trials (6)
-
Morning versus afternoon immunotherapy for advanced or metastatic solid tumors
This trial tests whether giving standard immune checkpoint inhibitor therapy in the morning versus the afternoon changes outcomes for adults with advanced or metastatic solid tumors.
-
Adebrelimab plus gemcitabine, cisplatin, and simvastatin for advanced biliary tract cancer
This trial tests whether adding adebrelimab and simvastatin to standard gemcitabine–cisplatin chemotherapy helps people with advanced biliary tract cancer.
-
MP0317 plus gemcitabine‑cisplatin and durvalumab for first-line advanced biliary tract cancer
This trial will test whether adding MP0317 to gemcitabine–cisplatin plus durvalumab helps people with unresectable or metastatic biliary tract cancer stay progression-free at 12 months.
-
At-home cancer treatment versus clinic-based treatment for advanced cancer patients
This study tests whether giving cancer treatment at home is better for comfort and satisfaction compared to getting it at a clinic for people with advanced cancer.
-
CPI-613 combined with hydroxychloroquine and chemotherapy for advanced solid tumors
This study is testing a new combination of treatments, including CPI-613 and hydroxychloroquine, to see if it can help people with advanced solid tumors that haven't improved with other chemotherapy.
-
Using olanzapine to help cancer patients regain appetite and manage weight loss
This study is testing if the medication olanzapine can help cancer patients who are losing weight and have a poor appetite feel better and gain weight while they are receiving treatment.
Related topics
Quick answers
How many Advanced Biliary Tract Carcinoma clinical trials are recruiting right now?
6, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 3 countries. The most sites are in United States (4 trials), France (1 trial), China (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 2: 4, Phase 1/2: 1, Phase 4: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.